|June 2022- Read the Deal Announcement
|Southeast Asia: Singapore
The global human microbiome market will witness a robust CAGR of 31.08%, valued at $115.42 million in 2021, expected to appreciate and reach $1318.72 million by 2030, confirms Strategic Market Research.
Core assets are used to power AMILI’s four commercial engines:
- Diagnostics and Therapeutics: AMILI works closely with academic institutions and biotech companies to identify novel biomarkers, elucidate mechanistic pathways and formulate products to modify the gut microbiome and treating disease.
- Fecal Microbiota Transplants (“FMT”): Collection, analysis and storage of FMT preparations used by patients, hospitals and research institutes across the region.
- Personalised Wellness: The direct-to-consumer arm of AMILI, branded as BIO & ME, which include sales of gut health testing services and personalised supplements.
- Consumer: Partnerships with Consumer Food Companies to assist them in product validation, measurement and developments. Providing them with insights to the impact of various ingredients, recipes and foods on the human microbiome, particularly as it pertains to the Asian consumer.
Impact linked to UN SDGs
Future Growth Prospects